Plasmin Proteolysis of Endothelial Cell and Vessel Wall Associated Tissue Factor Pathway Inhibitor

Summary Plasmin is an important protease that mediates clot fibrinolysis and vessel wall extracellular matrix proteolysis. Recently, in vitro studies have suggested that plasmin can cleave and inactivate recombinant TFPI, a major inhibitor of TF-mediated coagulation. We hypothesized that such an interaction may occur in vascular cells expressing TFPI, or in the vessel wall, with implications for thrombolysis. In a series of experiments, we examined the effects of plasmin on cell surface and extracellular matrix (ECM) associated TFPI in endothelial cells (EC) in culture and on EC and smooth muscle cells (SMC) in the vessel wall. Plasmin (0.2 μM) decreased cell surface and matrix associated TFPI activity in cultured endothelial cells by 77 ± 5 % and 69 ± 6% respectively (p < 0.01). Plasminogen, the proenzyme form of plasmin had no such effect on cell surface TFPI or matrix TFPI. Cell surface TFPI antigen measured by fluorescence activated cell sorter (FACS) was also significantly reduced by plasmin. Proteolysis of conditioned medium TFPI was suggested by loss of a ~45kD TFPI on Western Blot analysis following plasmin treatment. Plasmin also proteolysed a ~45kD TFPI protein in the intact ECM of EC, an effect which was inhibited by preincubation with aprotinin, a plasmin inhibitor. Incubation of similar concentrations of plasmin, with homogenates of normal vessel decreased a ~45kD TFPI immunoreactive band on Western blot analysis. Plasmin also decreased surface TFPI activity on frozen sections of normal vessel as measured by an amidolytic assay. Finally, plasmin treatment of atherosclerotic plaque sections caused complete removal of TFPI immunoreactivity associated with luminal EC and intimal SMC, when compared to control treated plaque (n = 3). Together these data suggest that plasmin proteolyses the majority of EC-associated (surface and matrix) TFPI and may remove TFPI from the luminal surface and intima of the vessel wall. TFPI proteolysis in cultured EC was associated with significant reduction in TFPI anticoagulant activity. These data provide evidence that plasmin degradation of TFPI occurs in vascular cells and in the vessel wall and may have implications for rethrombosis following thrombolysis in vivo.

[1]  V. Kakkar,et al.  Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Libby,et al.  CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. , 2000, The American journal of pathology.

[3]  W. Kisiel,et al.  Synthesis and Expression of Tissue Factor Pathway Inhibitor by Serum-stimulated Fibroblasts, Vascular Smooth Muscle Cells and Cardiac Myocytes , 1999, Thrombosis and Haemostasis.

[4]  G Murphy,et al.  Proteolysis and cell migration: creating a path? , 1999, Current opinion in cell biology.

[5]  J. Williams,et al.  Regulation of tissue factor pathway inhibitor expression in smooth muscle cells. , 1999, Blood.

[6]  R. Simari,et al.  Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. , 1998, Circulation research.

[7]  R. Simari,et al.  Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. , 1998, Circulation.

[8]  T. Wun,et al.  Proteolysis of Tissue Factor Pathway Inhibitor (TFPI) by Plasmin: Effect on TFPI Activity , 1998, Thrombosis and Haemostasis.

[9]  V. Ellis,et al.  Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells. , 1997, Blood.

[10]  H. Kojima,et al.  Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. , 1997, Circulation.

[11]  J. Giddings,et al.  Expression of von Willebrand factor, P-selectin (CD62P) and thrombomodulin in human endothelial cells in culture modulated by cyclosporin A. , 1997, Clinical and laboratory haematology.

[12]  P. Carmeliet,et al.  Insights in Vessel Development and Vascular Disorders Using Targeted Inactivation and Transfer of Vascular Endothelial Growth Factor, the Tissue Factor Receptor, and the Plasminogen System , 1997, Annals of the New York Academy of Sciences.

[13]  C. N. Rao,et al.  Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. , 1996, Archives of biochemistry and biophysics.

[14]  A. Schwartz,et al.  Receptor-mediated Endocytosis of Coagulation Factor Xa Requires Cell Surface-bound Tissue Factor Pathway Inhibitor (*) , 1996, The Journal of Biological Chemistry.

[15]  J. Sevinsky,et al.  Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor- dependent coagulation pathway , 1996, The Journal of cell biology.

[16]  J. Bognacki,et al.  Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  D. Pidard,et al.  Exposure of Human Platelets to Plasmin Results in the Expression of Irreversibly Active Fibrinogen Receptors , 1995, Thrombosis and Haemostasis.

[18]  A. Iorio,et al.  Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. , 1995, The Journal of laboratory and clinical medicine.

[19]  Eric J. Topol,et al.  Illusion of Reperfusion Does Anyone Achieve Optimal Reperfusion During Acute Myocardial Infarction? , 1993, Circulation.

[20]  R. Wesselschmidt,et al.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. , 1992, Blood.

[21]  H. Saito,et al.  Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Novotny,et al.  Regulation of coagulation by a multivalent Kunitz-type inhibitor. , 1990, Biochemistry.

[23]  L. Rosenfeld,et al.  Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. , 1990, The Journal of biological chemistry.

[24]  Susan G. Brown,et al.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor , 1989, Nature.

[25]  K. Mann,et al.  Activation/inactivation of human factor V by plasmin. , 1989, Blood.

[26]  M. L. Larsen,et al.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). , 1988, Thrombosis research.